Amicus Therapeutics Analyst Ratings
Amicus Therapeutics Analyst Ratings
Amicus Therapeutics Analyst Ratings
Amicus Therapeutics Analyst Ratings
Amicus Therapeutics Analyst Ratings
Morgan Stanley Upgrades Amicus Therapeutics to Overweight, Raises Price Target to $20
Amicus Therapeutics Analyst Ratings
Amicus Therapeutics: Strong Sales Performance and Future Profitability Hold Promise – A Buy Recommendation
Amicus Therapeutics Receives Buy Rating Amid Strong Q3 and Optimistic Full-Year Revenue Forecast
Amicus Therapeutics Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Amicus Therapeutics, Lowers Price Target to $14
Amicus Therapeutics Analyst Ratings
UBS Ups Price Target on Amicus Therapeutics to $20 From $19, Maintains Buy Rating
Amicus Therapeutics Analyst Ratings
UBS Adjusts Amicus Therapeutics Price Target to $19 From $17, Maintains Buy Rating
Morgan Stanley Reiterates Equal-Weight on Amicus Therapeutics, Maintains $15 Price Target
BofA Securities Adjusts Price Target on Amicus Therapeutics to $17 From $16, Maintains Buy Rating
The Latest Analyst Ratings for Amicus Therapeutics
B of A Securities Maintains Buy on Amicus Therapeutics, Raises Price Target to $17
Goldman Sachs Adjusts Amicus Therapeutics' Price Target to $11 From $10, Keeps Neutral Rating